Immunoblastic Lymphoma

This is a type of cancer that starts in the immune system cells called lymphocytes. It's a specific kind of non-Hodgkin lymphoma. Doctors diagnose it by looking at the cells under a microscope, which have a particular shape and size.

Condition

What people with Immunoblastic Lymphoma report

Every report comes from a Lived member, sent anonymously.

Have you had Chemotherapy infusion for Immunoblastic Lymphoma?

NameHow it went

About Immunoblastic Lymphoma

What It Is

Immunoblastic lymphoma is a fast-growing cancer of the lymph system, the network of lymph nodes and immune tissue that helps the body fight infection. It is a type of non-Hodgkin lymphoma that starts in B cells, the white blood cells that make antibodies. Under the microscope, the cancer is made up mostly of immunoblasts: large, activated immune cells with a big nucleus. The name comes from older classification systems, in which immunoblastic lymphoma was its own high-grade category. Today pathologists regard it as one variant of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, and a pathology report may use either name. DLBCL grows quickly, but it responds to treatment and is often curable. It usually shows up as an enlarging lump in a lymph node in the neck, armpit or groin, or in nodes inside the chest or abdomen, and it can also start in other organs such as the intestines, bones or brain. Fever, drenching night sweats and unexplained weight loss are common and are called B symptoms. Despite the similar name, angioimmunoblastic T-cell lymphoma is a different disease that starts in T cells and is treated differently.

Causes & Risk Factors

Most people with this lymphoma have no identifiable reason it developed. It begins when a B cell acquires genetic changes that let it keep dividing without the usual controls. Immunoblastic lymphomas more often carry a rearrangement of the MYC gene, which drives cell growth, than other forms of DLBCL. That change arises within the lymphoma cells and is useful to doctors for classification and outlook. The main known risk factors are older age (DLBCL is most often diagnosed in people in their 60s), male sex and a weakened immune system. Immune weakness can come from HIV, from medicines that suppress the immune system after an organ transplant, from autoimmune diseases such as rheumatoid arthritis or Sjögren syndrome, or from rare inherited immune disorders. Epstein-Barr virus, the virus behind mononucleosis, is linked to some lymphomas, particularly in people with weakened immunity. These are associations, not a sign that someone caused their lymphoma, and many people who develop it have none of them.

How It's Diagnosed

Lymphoma is diagnosed with a biopsy: removal of all or part of an enlarged lymph node, or a core of affected tissue taken with a wide needle. A pathologist examines the tissue under the microscope and uses stains for proteins on the cells (immunohistochemistry) to confirm that the cancer comes from B cells and to distinguish it from other lymphomas and from noncancerous swelling. Genetic tests on the sample look for rearrangements, including those involving MYC, because some combinations change how the lymphoma is classified and treated. Staging then shows how far the lymphoma has spread, from stage I (one area) to stage IV (widespread, or in organs such as the bone marrow or liver). A PET-CT scan, which highlights tissue that uses more sugar than normal, is the usual whole-body scan. Blood tests check blood counts, kidney and liver function and lactate dehydrogenase (LDH), an enzyme that tends to be higher when lymphoma is extensive or very active. Tests for HIV and hepatitis B and C are part of the workup because they affect treatment planning. Stage, LDH level, age and general health together help estimate outlook and guide how intensive treatment should be.

Treatment Options

Treatment aims to cure the lymphoma, and it usually starts soon after diagnosis because the cancer grows quickly. The standard first treatment is R-CHOP, given by infusion in repeated cycles over several months. It combines rituximab (Rituxan and biosimilars), an antibody that attaches to a protein called CD20 on B cells and marks them for destruction, with three chemotherapy drugs (cyclophosphamide, doxorubicin and vincristine) and the steroid prednisone. For people whose lymphoma carries a higher risk score, an alternative regimen swaps vincristine for polatuzumab vedotin (Polivy), an antibody that delivers a chemotherapy drug directly to lymphoma cells. In a large trial it kept more people free of lymphoma progression at two years than R-CHOP, though overall survival was about the same. Radiation therapy is sometimes added for disease limited to one area or for a large mass, and people at higher risk of the lymphoma spreading to the brain and spinal cord may be given extra treatment to prevent that. Some of the preparation is about safety. People are tested for hepatitis B before rituximab, because it can reactivate a past infection, and those at risk receive antiviral medicine or monitoring. Chemotherapy lowers white blood cell counts for part of each cycle, so infection is the main short-term danger, and medicines to prevent shingles and certain pneumonias are commonly prescribed. Doxorubicin can weaken the heart muscle, so heart health is considered when choosing treatment. Immunoblastic lymphoma is generally treated as DLBCL. Studies suggest it has a less favorable outlook than other forms after R-CHOP, partly because MYC rearrangements are more common, and genetic results can steer a doctor toward different or more intensive treatment. If the lymphoma does not respond or comes back, options include CAR T-cell therapy (a person's own immune cells engineered to attack the lymphoma), high-dose chemotherapy followed by a stem cell transplant, bispecific antibodies that link immune cells to lymphoma cells, and other targeted combinations. Clinical trials are worth asking about at diagnosis and at relapse.

What to Expect

Treatment is intensive but usually given as an outpatient, with an infusion visit every few weeks and blood tests in between. Tiredness, hair loss, nausea and a higher chance of infection are common during treatment, and numbness or tingling in the hands and feet can develop with some drugs. Many people continue some work and daily activities, but plans often need to flex around low-count days and recovery. A PET-CT scan partway through or at the end of treatment shows how well the lymphoma has responded. Aggressive lymphomas like this one are often cured, and when relapse happens it is most likely within the first two years. People with DLBCL who remain free of lymphoma two years after treatment go on to have a life expectancy similar to others of the same age and sex. Individual outlook depends on stage, age, general health and the lymphoma's genetic features, and the immunoblastic variant has done somewhat worse than other DLBCL in studies, so a specialist's estimate for the specific case matters more than averages. After treatment, follow-up visits continue for several years. Some effects can appear late: a lasting weakness of the immune system with more frequent infections, heart problems after doxorubicin, reduced fertility after some chemotherapy, and a higher long-term risk of other cancers. Anyone who may want children should raise fertility with the team before treatment begins.

When to Seek Help

See a doctor without delay for a lymph node that keeps enlarging over a few weeks, or for unexplained fevers, drenching night sweats or weight loss, since this lymphoma grows quickly and early treatment matters. During chemotherapy, call the care team right away, day or night, for a temperature of 100.5°F (38°C) or higher or shaking chills, because infections when white cell counts are low can become life threatening quickly. Check with the care team before taking acetaminophen or ibuprofen for a fever during treatment, since these can hide a fever that needs attention. After treatment, contact the care team about new swollen nodes, returning B symptoms or frequent infections rather than waiting for the next scheduled visit.

Questions to Ask Your Doctor

  1. 1.Does my pathology report show any MYC, BCL2 or BCL6 rearrangements, and how do those results change my treatment?
  2. 2.Is R-CHOP or the polatuzumab-based regimen a better fit for my stage and risk score, and why?
  3. 3.Am I at higher risk of the lymphoma reaching the brain or spinal cord, and do I need treatment to prevent that?
  4. 4.What should I do about fertility, my heart and infection prevention before treatment starts?
  5. 5.If the lymphoma does not respond or comes back, which options such as CAR T-cell therapy or a clinical trial would be open to me?

Last reviewed • Oct 2026

Educational content, not medical advice.